Table 4.
Multivariate analysis of overall survival.
| Multivariate Analysis * | Overall Survival | ||
|---|---|---|---|
| HR (95% CI) | Pr > Chi Square | ||
| Starting dose | Standard vs. reduced | 1.58 (1.19–2.08) | 0.0013 |
| Histology | Non-L-sarcoma vs. L-sarcoma | 1.64 (1.21–2.21) | 0.0014 |
| Response to trabectedin | PD vs. ORR | 3.39 (2.14–5.36) | <0.0001 |
| SD vs. ORR | 1.66 (1.04–2.66) | ||
| Lines of prior chemotherapy | 2 lines vs. 1 line | 1.31 (0.95–1.83) | 0.0175 |
| ≥3 lines vs. 1 line | 1.68 (1.15–2.45) | ||
* Multivariate analysis included only the variables that proved to be significant in univariate analyses using the following prognostic factors: starting dose of trabectedin, sarcoma histology, response to trabectedin, number of prior lines of chemotherapy, age, and pattern of metastases (lung vs. non-lung). CI, confidence interval; HR, hazard ratio; ORR, overall response rate; PD, progressive disease; SD, stable disease.